RecruitingNot Applicable

Visual Plasticity Following Brain Lesions

United States30 participantsStarted 2025-07-17

Plain-language summary

The VIBRANT (Vision Improvement through Behavioral Rehabilitation And Neuroplasticity Training) study is a prospective, double-blind, crossover design (within-subject) in participants with homonymous hemianopia-a type of visual field loss resulting from damage to the post-chiasmatic visual pathways. It aims to investigate whether transcranial random noise stimulation (tRNS) combined with perceptual learning-based training has potential for improving visual impairments.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. At least 18 years of age.
✓. Capable of providing informed consent and complying with study procedures.
✓. Unilateral or bilateral focal brain damage causing loss of vision.
✓. At least three months post-stroke or traumatic brain injury, or a stable brain tumor within the past year.

Exclusion criteria

✕. Severe CNS diseases or disorders unrelated to the focal lesion, which could interfere with study results.
✕. Severe mental health challenges that could interfere with study results, or current or recent (within the past 6 months) drug or alcohol abuse or addiction as defined by DSM-5.
✕. Vision loss resulting from ocular disease or disorder.
✕. At least 18 years of age.
✕. Capable of providing informed consent and complying with study procedures.
✕. Any CNS diseases or psychiatric disorders (e.g., epilepsy, schizophrenia) that would interfere with study results.
✕. Previous head injury.
✕. Present or past (within past 6 months) drug or alcohol abuse or addiction based on DSM-5.

What they're measuring

Change in Motion Discrimination Performance

Timeframe: Study visit 1 to 2 (within a week), and study visit 3 to 4 (within a week)

Trial details

NCT IDNCT07105358

SponsorGeorgetown University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-06-30

Contact for this trial

Tina Liu, PhD

2027849920 tina.liu@georgetown.edu

View on ClinicalTrials.gov More Visual Field Defect trials